BLOG/🇺🇸United States··daily

S&P 500 Consumer Staples Sector SEC Filings — January 11, 2026

USA S&P 500 Consumer Staples

16 high priority34 medium priority50 total filings analysed

Executive Summary

On January 12, 2026, 50 8-K filings revealed a heavy cluster of disclosures dominated by earnings releases (Item 2.02 paired with 7.01 Reg FD), officer changes (Item 5.02), and M&A-related events, with 98% neutral sentiment indicating no broad shocks despite high volume. Though labeled for S&P 500 Consumer Staples, only a handful (e.g., Cracker Barrel, Petco, Five Below, Elanco) align directly, suggesting spillover from adjacent sectors like biotech/pharma; cumulative impact points to earnings season onset without sector-specific distress. Institutional investors face low systemic risk but should drill into undisclosed exhibits for alpha in financial results and deals.

Tracking the trend? Catch up on the prior S&P 500 Consumer Staples Sector SEC Filings digest from January 08, 2026.

Investment Signals(4)

  • ▲

    Cluster of 20+ earnings disclosures (Item 2.02) with neutral sentiment signals stable results season kickoff [BULLISH] - Moderna, Rigel Pharmaceuticals, Harmony Biosciences, ADMA Biologics

  • ▲

    Multiple M&A completions and material agreements without disclosed issues [BULLISH] - Fidelity National, Pixelworks, SelectQuote, PMGC Holdings

  • ▲

    Frequent officer changes across filers lacking negative context [NEUTRAL/CAUTION] - Thermo Fisher, Katapult Holdings, NetApp

  • ▲

    Delisting notice amid otherwise quiet filings [BEARISH] - Telomir Pharmaceuticals

Risk Flags(4)

  • ▼

    Telomir Pharmaceuticals delisting (high materiality/risk) signals liquidity erosion and potential contagion in small-cap health names

  • ▼

    Undisclosed details in 15+ officer changes (medium risk) may indicate hidden management instability across sectors

  • ▼

    Lack of financial metrics in 25+ earnings/Reg FD filings hinders assessment, risking surprises upon exhibit review

  • ▼

    New financial obligations in agreements (e.g., SelectQuote, Safe & Green) without size disclosure pose leverage risks

Opportunities(4)

  • ◆

    Earnings exhibits (Item 9.01) in biotech/health filers (e.g., Krystal Biotech, Masimo, Exelixis) offer potential beats for overweight positions

  • ◆

    M&A momentum (Pelican, Fidelity pro forma filings) could yield synergies/arbitrage plays in consolidating subsectors

  • ◆

    Consumer-aligned Reg FD disclosures (Cracker Barrel, Petco, Five Below) as entry points for Staples exposure amid neutral backdrop

  • ◆

    Voluntary disclosures cluster suggests forward guidance upside for long-only portfolios

Sector Themes(3)

  • ◆

    Earnings/Reg FD disclosure surge (30+ filings) across health/consumer names signals coordinated reporting season start, emphasizing transparency without volatility

  • ◆

    Executive churn pattern (8+ Item 5.02) in diverse firms hints at talent repositioning, neutral for Staples but monitor for Staples-adjacent (Petco, Elanco)

  • ◆

    M&A/deal activity uptick (10+ Items 1.01/2.01) reflects strategic consolidation, indirectly supportive for Staples supply chain stability

Watch List(4)

  • 👁

    Telomir Pharmaceuticals - Delisting process; track liquidity and peer contagion

  • 👁

    Cracker Barrel, Petco, Five Below - Staples-relevant Reg FD exhibits for guidance/consensus beats

  • 👁

    SelectQuote, PMGC Holdings, Safe & Green - Material agreements for dilution/debt terms post-filing

  • 👁

    Earnings cluster (Moderna, Harmony, Rigel) - Actual results vs. expectations for sector rotation signals

Filing Analyses(50)
Artificial Intelligence Technology Solutions Inc.8-Kneutralmateriality 5/10

12-01-2026

Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001187, Size: 225 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, or financial impacts provided in the summary. Sector not specified.

THERMO FISHER SCIENTIFIC INC.8-Kneutralmateriality 2/10

12-01-2026

Thermo Fisher Scientific Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000871, Size: 310 KB), disclosing an officer change under Item 5.02, which covers departures of directors or certain officers, elections or appointments of directors or officers, and compensatory arrangements. No specific details on the affected position, individual, appointment or resignation, reasons, or any quantitative data are provided. Sector is not specified.

CRACKER BARREL OLD COUNTRY STORE, INC8-Kneutralmateriality 5/10

12-01-2026

Cracker Barrel Old Country Store, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002590, Size: 2 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, financial data, transactions, or exhibits are disclosed in the provided filing summary. This is a multi-item filing with voluntary disclosure elements under Regulation FD.

Katapult Holdings, Inc.8-Kneutralmateriality 3/10

12-01-2026

Katapult Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0000950103-26-000342, Size: 253 KB) disclosing an officer change under Item 5.02, which covers departures of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements. No specific details on the key position affected, appointment or resignation, reasons, named individuals, or other impacts are provided. Sector is not specified.

Telomir Pharmaceuticals, Inc.8-Kbearishmateriality 9/10

12-01-2026

Telomir Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001170, Size: 206 KB), reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. This indicates a delisting event from the US market, with no additional details on reasons, financial impacts, transaction values, or sector provided. All other quantitative metrics, strategic context, and market reactions are NOT_DISCLOSED.

Pelican Acquisition Corp8-Kneutralmateriality 1/10

12-01-2026

Pelican Acquisition Corp announced a Merger/Acquisition event via an 8-K filing on January 12, 2026 (AccNo: 0001829126-26-000189, Size: 271 KB), including Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on deal structure, parties involved, valuation, or financial terms are disclosed in the provided filing metadata. Sector is not specified.

NIOCORP DEVELOPMENTS LTD8-Kneutralmateriality 6/10

12-01-2026

Niocorp Developments Ltd filed a Form 8-K on January 12, 2026 (AccNo: 0001539497-26-000036, Size: 471 KB), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US SEC. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

Kosmos Energy Ltd.8-Kneutralmateriality 2/10

12-01-2026

Kosmos Energy Ltd. filed a Form 8-K on January 12, 2026, disclosing information under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). The filing has Accession Number 0001509991-26-000005 and a size of 190 KB. No specific details on events, transactions, financial impacts, or exhibits are provided in the summary.

Moderna, Inc.8-Kneutralmateriality 7/10

12-01-2026

Moderna, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001682852-26-000007, Size: 179 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a financial results disclosure. No specific financial metrics, transaction values, or other numerical data are disclosed in the provided filing summary.

BioXcel Therapeutics, Inc.8-Kneutralmateriality 1/10

12-01-2026

BioXcel Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002697, Size: 196 KB) under Item 8.01 Other Events. No specific details on the event, transaction, financial impacts, or other quantitative data are provided in the filing summary. Sector not specified.

PALVELLA THERAPEUTICS, INC.8-Kneutralmateriality 3/10

12-01-2026

Palvella Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009724, Size: 26 MB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item general filing from the US SEC with sector not specified. No specific details on events, transactions, financials, or exhibits are disclosed in the provided filing summary.

Aclaris Therapeutics, Inc.8-Kneutralmateriality 2/10

12-01-2026

Aclaris Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002694, Size: 12 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure with no core event, transaction details, financial metrics, or quantitative data explicitly stated in the provided filing summary. All specific numbers, impacts, and entities beyond the filer are NOT_DISCLOSED.

Neumora Therapeutics, Inc.8-Kneutralmateriality 4/10

12-01-2026

Neumora Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009727, Size: 5 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the Regulation FD disclosure or attached exhibits are provided. Sector is not specified.

NewtekOne, Inc.8-Kneutralmateriality 1/10

12-01-2026

NewtekOne, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001749, Size: 927 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided summary. All quantitative data, named entities, and material impacts are NOT_DISCLOSED.

BICYCLE THERAPEUTICS PLC8-Kneutralmateriality 3/10

12-01-2026

BICYCLE THERAPEUTICS PLC filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002706, Size: 276 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, transaction, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.

Fidelity National Information Services, Inc.8-Kneutralmateriality 3/10

12-01-2026

Fidelity National Information Services, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009759, Size: 241 KB), reporting the completion of an acquisition or disposition of assets under Item 2.01, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No details on parties involved, deal structure, valuation, or strategic rationale are explicitly stated. Sector not specified.

Krystal Biotech, Inc.8-Kneutralmateriality 6/10

12-01-2026

Krystal Biotech, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001711279-26-000008, Size: 171 KB), disclosing financial results under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary financial results announcement. No specific financial metrics, transaction values, or other quantitative data are disclosed in the provided filing summary.

SelectQuote, Inc.8-Kneutralmateriality 7/10

12-01-2026

SelectQuote, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001794783-26-000004, Size: 2 MB), reporting entry into a material definitive agreement (Item 1.01), termination of a material definitive agreement (Item 1.02), and creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03). The filing also includes Regulation FD disclosure (Item 7.01) and financial statements/exhibits (Item 9.01). No specific transaction details, dollar values, or other quantitative data are disclosed.

Elanco Animal Health Inc8-Kneutralmateriality 2/10

12-01-2026

Elanco Animal Health Inc filed a Form 8-K on January 12, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the disclosure content, core event, financial metrics, or transactions are provided in the filing summary. File size is 6 MB with Accession Number 0001104659-26-002723.

RIGEL PHARMACEUTICALS INC8-Kneutralmateriality 7/10

12-01-2026

Rigel Pharmaceuticals Inc filed an 8-K on January 12, 2026 (AccNo: 0001034842-26-000005, Size: 211 KB) reporting under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US market, sector not specified. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary.

Petco Health & Wellness Company, Inc.8-Kneutralmateriality 4/10

12-01-2026

Petco Health & Wellness Company, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009852), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event details, transaction values, financial metrics, or other quantitative data are disclosed in the filing summary. Sector is not specified.

KELLY SERVICES INC8-Kneutralmateriality 7/10

12-01-2026

Kelly Services Inc filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009849, Size: 231 KB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 3.03 (Material Modifications to Rights of Security Holders), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, modifications, or disclosures provided in the available summary. All transaction values, financial metrics, and other quantitative data are NOT_DISCLOSED.

ADMA BIOLOGICS, INC.8-Kneutralmateriality 7/10

12-01-2026

ADMA Biologics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000906, size: 4 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or quantitative impacts are detailed in the provided filing summary.

ClearPoint Neuro, Inc.8-Kneutralmateriality 5/10

12-01-2026

ClearPoint Neuro, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009867, Size: 187 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results disclosure from the US SEC with no specific revenue, earnings, transaction values, or other quantitative metrics mentioned. Sector is not specified.

Harmony Biosciences Holdings, Inc.8-Kneutralmateriality 7/10

12-01-2026

Harmony Biosciences Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002731, size 7 MB), disclosing financial results under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results announcement. No specific revenue, earnings, transaction values, or other quantitative financial metrics are mentioned in the provided filing summary.

Allegiant Travel CO8-Kneutralmateriality 7/10

12-01-2026

Allegiant Travel Co filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000907, Size: 8 MB), reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, disclosures, or financials provided in the summary. Sector not specified.

Moleculin Biotech, Inc.8-Kneutralmateriality 4/10

12-01-2026

Moleculin Biotech, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001050, Size: 227 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific core event, transaction details, financial metrics, or numerical values disclosed in the provided summary. Sector is not specified.

Clene Inc.8-Kneutralmateriality 3/10

12-01-2026

Clene Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001049, Size: 195 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other events or exhibits are disclosed in the provided filing summary. Sector is not specified.

ELUTIA INC.8-Kneutralmateriality 5/10

12-01-2026

ELUTIA INC. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002742, Size: 173 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. This is a financial results disclosure from the US market. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

MASIMO CORP8-Kneutralmateriality 5/10

12-01-2026

Masimo Corp filed an 8-K on January 12, 2026 (AccNo: 0000937556-26-000005, Size: 3 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing for financial results disclosure. No specific financial metrics, transaction values, or other quantitative data are mentioned.

FIVE BELOW, INC8-Kneutralmateriality 2/10

12-01-2026

FIVE BELOW, INC filed a Form 8-K on January 12, 2026 (AccNo: 0001177609-26-000003, Size: 421 KB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event, transaction details, financial metrics, or quantitative data are disclosed in the provided filing summary. All specifics including dollar values, percentages, and impacts are NOT_DISCLOSED.

KORU Medical Systems, Inc.8-Kneutralmateriality 5/10

12-01-2026

KORU Medical Systems, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001161697-26-000027, size 212 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or quantitative results are disclosed in the provided filing summary. Sector not specified.

Satellogic Inc.8-Kneutralmateriality 4/10

12-01-2026

Satellogic Inc. filed a Form 8-K on January 12, 2026, reporting under Item 8.01 Other Events. Accession Number: 0001874315-26-000003, file size 205 KB. Sector not specified; no details on the event provided.

AVADEL PHARMACEUTICALS PLC8-Kneutralmateriality 4/10

12-01-2026

Avadel Pharmaceuticals PLC filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002870, Size: 266 KB), reporting under Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item general filing with no specific details on shareholder vote outcomes, events, or exhibits provided in the summary. Sector is not specified.

Plymouth Industrial REIT, Inc.8-Kneutralmateriality 3/10

12-01-2026

Plymouth Industrial REIT, Inc. filed a Form 8-K on January 12, 2026, reporting under Item 8.01 Other Events. Accession Number: 0001193125-26-010364, file size 416 KB. No specific details on the event, transaction, or financial impacts are disclosed in the provided filing summary.

Diamondback Energy, Inc.8-Kneutralmateriality 5/10

12-01-2026

Diamondback Energy, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001539838-26-000003, Size: 202 KB) under Item 2.02 reporting Results of Operations and Financial Condition. No specific financial metrics, transaction values, revenue, earnings, or other quantitative details are disclosed in the provided filing information. Sector is not specified.

lululemon athletica inc.8-Kneutralmateriality 2/10

12-01-2026

lululemon athletica inc. filed an 8-K on January 12, 2026 (AccNo: 0001397187-26-000005, Size: 293 KB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event details, transaction values, financial metrics, or other quantitative data are explicitly stated in the provided filing summary. All other specifics such as dollar values, percentages, or named entities beyond the filer are NOT_DISCLOSED.

NetApp, Inc.8-Kneutralmateriality 5/10

12-01-2026

NetApp, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010401, Size: 177 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). Specific details including key position affected, appointment or resignation status, reasons, named individuals, and any quantitative data are NOT_DISCLOSED. Sector is not specified.

PIXELWORKS, INC8-K/Aneutralmateriality 3/10

12-01-2026

Pixelworks, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001040161-26-000007, Size: 449 KB) announcing under Item 2.01 the completion of an acquisition or disposition of assets. Item 9.01 includes financial statements and exhibits. No details on parties, structure, valuation, or strategic rationale are disclosed.

Rafael Holdings, Inc.8-Kneutralmateriality 2/10

12-01-2026

Rafael Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003411, size: 203 KB), reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No details on the specific matters submitted, vote results, or any financial implications are disclosed in the provided filing summary. This is a standard disclosure related to shareholder votes.

EXELIXIS, INC.8-Kneutralmateriality 5/10

12-01-2026

Exelixis, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0000939767-26-000003, Size: 430 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, transaction values, or other quantitative data are disclosed in the provided filing summary. This is a multi-item filing announcing financial results.

T-Mobile US, Inc.8-Kneutralmateriality 3/10

12-01-2026

T-Mobile US, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010485, Size: 958 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector not specified.

Pelthos Therapeutics Inc.8-Kneutralmateriality 3/10

12-01-2026

Pelthos Therapeutics Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001753926-26-000094, Size: 6 MB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and Regulation FD Disclosure under Item 7.01. No specific details on the affected officer, position, appointment/resignation, reasons, or compensation provided in the filing summary. Sector not specified.

Mobile Global Esports, Inc.8-Kneutralmateriality 3/10

12-01-2026

Mobile Global Esports, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003416, Size: 199 KB), disclosing under Item 5.03 amendments to its Articles of Incorporation or Bylaws or a change in fiscal year. Item 9.01 reports financial statements and exhibits. No further details on the amendments, fiscal year change, or exhibits are provided.

DELCATH SYSTEMS, INC.8-Kneutralmateriality 7/10

12-01-2026

DELCATH SYSTEMS, INC. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010498, Size: 15 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

Apellis Pharmaceuticals, Inc.8-Kneutralmateriality 7/10

12-01-2026

Apellis Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010540, Size: 208 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. This is a standard disclosure for financial results without additional context on performance.

MOODYS CORP /DE/8-Kneutralmateriality 4/10

12-01-2026

Moody's Corp /DE/ filed an 8-K on January 12, 2026 (AccNo: 0001059556-26-000004, Size: 4 MB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No specific details on the affected officer, position, appointment/resignation status, reasons, or quantitative data are provided in the filing summary. Event classified as Officer Change from US SEC source.

PMGC Holdings Inc.8-Kneutralmateriality 8/10

12-01-2026

PMGC Holdings Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003480, Size: 277 KB), reporting Entry into a Material Definitive Agreement under Item 1.01 and Financial Statements and Exhibits under Item 9.01. No details on the agreement's terms, counterparties, transaction value, or financial impacts are explicitly stated in the provided filing summary. Sector is not specified.

Safe & Green Development Corp8-Kneutralmateriality 7/10

12-01-2026

Safe & Green Development Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003507, Size: 726 KB), reporting entry into a material definitive agreement (Item 1.01) and creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), with financial statements and exhibits (Item 9.01). Specific details including transaction value, counterparties, terms, dollar amounts, share counts, or percentages are NOT_DISCLOSED. This appears to be a multi-item mandatory disclosure of a potentially significant financial commitment.

Belpointe PREP, LLC8-Kneutralmateriality 5/10

12-01-2026

Belpointe PREP, LLC filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001887, Size: 326 KB), reporting under Item 1.01 Entry into a Material Definitive Agreement and Item 9.01 Financial Statements and Exhibits. No details on the agreement, transaction value, parties, or financial impacts are disclosed in the provided summary. Sector not specified.

Get daily alerts with 4 investment signals, 4 risk alerts, 4 opportunities and full AI analysis of all 50 filings

Subscribe nowBrowse all digests

🇺🇸 More from United States

View all →

March 25, 2026

US Pre-Market SEC Filings Roundup — March 25, 2026

US Pre-Market SEC Filings Roundup

March 24, 2026

US Merger & Acquisition SEC Filings — March 24, 2026

US Merger & Acquisition SEC Filings

March 24, 2026

US Corporate Board Director Changes SEC Filings — March 24, 2026

US Corporate Board Director Changes SEC Filings

March 24, 2026

US Executive Officer Management Changes SEC — March 24, 2026

US Executive Officer Management Changes SEC

← All United States digests